Suppr超能文献

美国去甲肾上腺素短缺与脓毒性休克患者死亡率之间的关联。

Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock.

机构信息

Department of Anesthesiology, Columbia University, New York, New York.

Department of Medicine, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York3Department of Neurology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York.

出版信息

JAMA. 2017 Apr 11;317(14):1433-1442. doi: 10.1001/jama.2017.2841.

Abstract

IMPORTANCE

Drug shortages in the United States are common, but their effect on patient care and outcomes has rarely been reported.

OBJECTIVE

To assess changes to patient care and outcomes associated with a 2011 national shortage of norepinephrine, the first-line vasopressor for septic shock.

DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study of 26 US hospitals in the Premier Healthcare Database with a baseline rate of norepinephrine use of at least 60% for patients with septic shock. The cohort included adults with septic shock admitted to study hospitals between July 1, 2008, and June 30, 2013 (n = 27 835).

EXPOSURES

Hospital-level norepinephrine shortage was defined as any quarterly (3-month) interval in 2011 during which the hospital rate of norepinephrine use decreased by more than 20% from baseline.

MAIN OUTCOMES AND MEASURES

Use of alternative vasopressors was assessed and a multilevel mixed-effects logistic regression model was used to evaluate the association between admission to a hospital during a norepinephrine shortage quarter and in-hospital mortality.

RESULTS

Among 27 835 patients (median age, 69 years [interquartile range, 57-79 years]; 47.0% women) with septic shock in 26 hospitals that demonstrated at least 1 quarter of norepinephrine shortage in 2011, norepinephrine use among cohort patients declined from 77.0% (95% CI, 76.2%-77.8%) of patients before the shortage to a low of 55.7% (95% CI, 52.0%-58.4%) in the second quarter of 2011; phenylephrine was the most frequently used alternative vasopressor during this time (baseline, 36.2% [95% CI, 35.3%-37.1%]; maximum, 54.4% [95% CI, 51.8%-57.2%]). Compared with hospital admission with septic shock during quarters of normal use, hospital admission during quarters of shortage was associated with an increased rate of in-hospital mortality (9283 of 25 874 patients [35.9%] vs 777 of 1961 patients [39.6%], respectively; absolute risk increase = 3.7% [95% CI, 1.5%-6.0%]; adjusted odds ratio = 1.15 [95% CI, 1.01-1.30]; P = .03).

CONCLUSIONS AND RELEVANCE

Among patients with septic shock in US hospitals affected by the 2011 norepinephrine shortage, the most commonly administered alternative vasopressor was phenylephrine. Patients admitted to these hospitals during times of shortage had higher in-hospital mortality.

摘要

重要性

美国药品短缺很常见,但它们对患者护理和结果的影响很少有报道。

目的

评估 2011 年去甲肾上腺素短缺(脓毒性休克的一线升压药)对患者护理和结果的改变。

设计、地点和参与者:在 Premier Healthcare Database 中,对 26 家美国医院进行了回顾性队列研究,这些医院在基线时至少有 60%的脓毒性休克患者使用去甲肾上腺素。该队列包括在研究医院因脓毒性休克入院的成年人,时间为 2008 年 7 月 1 日至 2013 年 6 月 30 日(n=27835)。

暴露

医院级别的去甲肾上腺素短缺定义为 2011 年任何一个季度(3 个月),在此期间,医院去甲肾上腺素使用率比基线下降超过 20%。

主要结果和测量

评估了替代升压药的使用情况,并使用多水平混合效应逻辑回归模型评估了在去甲肾上腺素短缺季度入院与院内死亡率之间的关系。

结果

在 26 家医院的 27835 名患有脓毒性休克的患者中(中位数年龄为 69 岁[四分位距,57-79 岁];47.0%为女性),至少有 1 个季度在 2011 年出现去甲肾上腺素短缺,队列患者中去甲肾上腺素的使用率从短缺前的 77.0%(95%CI,76.2%-77.8%)降至 2011 年第二季度的 55.7%(95%CI,52.0%-58.4%);在此期间,苯肾上腺素是最常使用的替代升压药(基线时为 36.2%[95%CI,35.3%-37.1%];最高时为 54.4%[95%CI,51.8%-57.2%])。与在正常使用季度期间因脓毒性休克入院相比,在短缺季度期间入院与院内死亡率增加相关(分别为 25874 名患者中的 9283 名[35.9%]和 1961 名患者中的 777 名[39.6%];绝对风险增加=3.7%[95%CI,1.5%-6.0%];调整后的优势比=1.15[95%CI,1.01-1.30];P=0.03)。

结论和相关性

在美国受 2011 年去甲肾上腺素短缺影响的医院中,脓毒性休克患者最常使用的替代升压药是苯肾上腺素。在这些医院短缺期间入院的患者院内死亡率更高。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验